Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
HCC38 Neratinib
1.0
EGFR/HER2
RTK
 0.8500 0.00141
HCC38 Neratinib
3.1623
EGFR/HER2
RTK
 0.4571 0.08465
HCC38 Tivantinib
0.001
MET
RTK
 1.0179 0.00248
HCC38 Tivantinib
0.0031623
MET
RTK
 1.0366 0.00911
HCC38 Tivantinib
0.01
MET
RTK
 1.0588 -0.00191
HCC38 Tivantinib
0.031623
MET
RTK
 0.9481 0.00115
HCC38 Tivantinib
0.1
MET
RTK
 0.9036 0.02356
HCC38 Tivantinib
0.31623
MET
RTK
 0.4905 0.11591
HCC38 Tivantinib
1.0
MET
RTK
 -0.0742 0.31420
HCC38 Tivantinib
3.1623
MET
RTK
 -0.2218 0.41201
HCC38 Tivantinib
10.0
MET
RTK
 -0.2702 0.29101
HCC38 Cediranib
0.001
VEGFR/cKIT
RTK
 1.0723 -0.00376
HCC38 Cediranib
0.0031623
VEGFR/cKIT
RTK
 1.0633 0.00639
HCC38 Cediranib
0.01
VEGFR/cKIT
RTK
 1.0421 -0.00369
HCC38 Cediranib
0.031623
VEGFR/cKIT
RTK
 1.0834 -0.00314
HCC38 Cediranib
0.1
VEGFR/cKIT
RTK
 0.9847 0.00854
HCC38 Cediranib
0.31623
VEGFR/cKIT
RTK
 0.9247 -0.00033
HCC38 Cediranib
1.0
VEGFR/cKIT
RTK
 0.5790 0.03479
HCC38 Cediranib
3.1623
VEGFR/cKIT
RTK
 0.2701 0.04648
HCC38 Cediranib
10.0
VEGFR/cKIT
RTK
 -0.2044 0.28905
HCC38 Cabozantinib
0.001
VEGFR2/MET
RTK
 0.9746 0.00029
HCC38 Cabozantinib
0.0031623
VEGFR2/MET
RTK
 0.9922 -0.01243
HCC38 Cabozantinib
0.01
VEGFR2/MET
RTK
 1.0057 -0.00213
HCC38 Cabozantinib
0.031623
VEGFR2/MET
RTK
 0.9940 -0.00860
HCC38 Cabozantinib
0.1
VEGFR2/MET
RTK
 0.9857 0.00098